Olsson, N., Heberling, M.L., Zhang, L., Jhunjhunwala, S., Phung, Q.T., Lin, S., Anania, V.G., Lill, J.R. and Elias, J.E. Frontiers in Immunology 12 (2021): 662443.
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, South San Francisco, CA, United States
- Department of OMNI Biomarker Development, Genentech, South San Francisco, CA, United States
In total 30 synthetic peptides covering a total of 22 SNP sites and two potential neoantigens, were purchased from CPC Scientific (Sunnyvale, CA) with a purity of >70%, dissolved in 0.1% FA and quality checked at a concentration of 250 fmol by mass spectrometry.
to Manufacture Neoantigen Peptides for the PANDA (Personalized and Adaptive) Cancer Vaccine Program.
SUNNYVALE, California, Feb. 19, 2019 – CPC Scientific Inc., a leading global CDMO specializing in synthetic peptide manufacturing, announced today that they will manufacture GMP-grade neoantigen peptides for investigators at UNC Lineberger Comprehesive Cancer Center (LCCC) for the purpose of individualized immunotherapy. CPC […]
